GSK
GSK plc$52.04
LiveJun 16, 2026
Market cap
$104.31B
52w range
35.45 – 61.70
P / E
—
EPS
—
Volume
716.85K
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on GSK plc’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $52.45 (+0.79%)
Candlestick · 1Y
Open in chart workstation →GSK
52.23-0.46%H 61.70L 48.57MA50 52.98MA200 —Avg vol 4.9M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.36% | +0.46% | +5.54% | -2.51% | +7.46% | +6.89% | +29.46% | +49.13% | +28.92% | +29.21% | +7887.81% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$52.04
1,990 sh
Bid
$51.63
1,200 sh
Ask
$52.45
1,200 sh
Spread
$0.820
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Financial Services+1.26%
- Utilities+0.83%
- Communication Services+0.46%
- Energy+0.45%
- Technology+0.34%
- Consumer Defensive-0.21%
- Industrials-0.32%
- Healthcare-0.39%
- Real Estate-0.67%
- Consumer Cyclical-0.94%
- Basic Materials-1.06%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-0.68%
- Department Stores-6.26%
- Broadcasting-4.30%
- Education & Training Services-3.71%
- Medical - Equipment & Services+3.71%
- Solar-3.63%
- Electronic Gaming & Multimedia+3.56%
- Steel-3.33%
- Real Estate - Development-3.31%
- Trucking-3.16%
- Copper-3.02%
- Coal-2.91%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorderzacks.com·Jun 12, 2026
- Is GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says Overvaluedgurufocus.com·Jun 11, 2026
- Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billionmarketbeat.com·Jun 11, 2026
- Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent dealreuters.com·Jun 11, 2026
- GSK plc (GSK) M&A Call Transcriptseekingalpha.com·Jun 10, 2026
- GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analystsproactiveinvestors.co.uk·Jun 10, 2026
- After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion dealwsj.com·Jun 09, 2026
- GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyoutzacks.com·Jun 09, 2026
Recent analyst activity
DB- Jun 09, 2026GradeOutperform → OutperformRBC Capital: 'On balance we think readthroughs from the GSK acquisition of NUVB's key competitor are positive'RBC Capital
Peers
No peer list available for GSK.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|